Tejeda v. Secretary of Health and Human Services

Opinion

In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS No. 20-525V Filed: December 22, 2025

Special Master Horner ROBERTO A. TEJEDA,

Petitioner, v.

SECRETARY OF HEALTH AND HUMAN SERVICES,

Respondent.

Scot Tyler Scheuerman, Scheuerman Law Firm, PLLC, San Antonio, TX, for petitioner. Benjamin Patrick Warder, U.S. Department of Justice, Washington, DC, for respondent.

DECISION AWARDING ATTORNEYS’ FEES AND COSTS1

On April 28, 2020, petitioner filed a petition for compensation under the National Vaccine Injury Compensation Program, 42 U.S.C. § 300aa-10, et seq.2 (“Vaccine Act”). (ECF No. 1.) Petitioner alleged that he suffered Guillain Barre Syndrome (“GBS”) as a result of his December 29, 2017 influenza (“flu”) vaccination. (Id.) On December 1, 2022, petitioner was awarded interim attorneys’ fees and costs totaling $72,793.75. (ECF No. 50.) On March 25, 2025, the undersigned issued a decision denying compensation. (ECF No. 64.) On April 14, 2025, petitioner filed a motion seeking an award of final attorneys’ fees and costs. (ECF No. 67.) Petitioner seeks $41,343.70, including $30,750.00 for attorneys’ fees and $10,593.70 for attorneys’ costs. (Id.)

Respondent filed his response on April 23, 2025. (ECF No. 69.) Respondent agrees that the statutory requirements for an award of attorneys’ fees and costs have 1 Because this document contains a reasoned explanation for the action taken in this case, it must be made publicly accessible and will be posted on the United States Court of Federal Claims' website, and/or at https://www.govinfo.gov/app/collection/uscourts/national/cofc, in accordance with the E-Government Act of 2002. 44 U.S.C. § 3501 note (2018) (Federal Management and Promotion of Electronic Government Services). This means the document will be available to anyone with access to the internet. In accordance with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information, the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that the identified material fits within this definition, I will redact such material from public access. 2 Within this decision, all citations to § 300aa will be to the relevant sections of the Vaccine Act at 42 U.S.C. § 300aa-10, et seq.

1 been met. (Id. at 3.) Noting the special master’s discretion regarding attorneys’ fees and costs and cautioning that determination of fees “should not result in a second major litigation,” “[r]espondent therefore respectfully requests that the Court exercise its discretion and determine a reasonable award for attorneys’ fees and costs.” (Id. at 3-4 (quoting Fox v. Vice, 563 U.S. 826, 838 (2011)).)

The undersigned has reviewed the billing records submitted with petitioner’s request. (ECF No. 67-2.) In the undersigned’s experience, the request appears reasonable overall, and the undersigned finds no cause to reduce the requested hours or rates. Additionally, pursuant to Vaccine Rule 13(a)(3), “[t]he failure of respondent to identify with particularity any objection to a request for attorney’s fees and costs may be taken into consideration by the special master in the decision.” The costs also appear to be reasonable and sufficiently documented. (ECF No. 67-3.)

The Vaccine Act permits an award of reasonable attorneys’ fees and costs. § 300aa-15(e). Based on the reasonableness of petitioner’s request, the undersigned GRANTS petitioner’s motion for attorneys’ fees and costs.

Accordingly, the undersigned awards a lump sum of $41,343.70, representing reimbursement of attorneys’ fees and costs, to be paid through an ACH deposit to petitioner’s counsel of record, Scot Tyler Scheuerman’s IOLTA account for prompt disbursement.

The clerk of the court shall enter judgment in accordance herewith.3

IT IS SO ORDERED.

s/Daniel T. Horner Daniel T. Horner Special Master

3 Pursuant to Vaccine Rule 11(a), entry of judgment can be expedited by the parties’ joint filing of notice renouncing the right to seek review.